VivoSeq
Other

Stereotactic Body Radiotherapy

0

Pipeline Programs↗

8

Active Trials↗

0

Companies Involved↗

Stereotactic Body Radiotherapy is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

7/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Recruiting4 · 29%
Active, not recruiting3 · 21%
Unknown status3 · 21%
Completed2 · 14%
Withdrawn1 · 7%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Recruiting·—·Phase 2·NCT04830267·39 enrolled
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
Recruiting·—·Phase 2·NCT04933903·25 enrolled
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Recruiting·ZZhejiang Cancer Hospital·N/A·NCT06349044·120 enrolled
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03808337·145 enrolled
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05678010·54 enrolled
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
Active, not recruiting·UUniversity of Chicago·Phase 1·NCT02608385·117 enrolled
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT03148327·18 enrolled
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
Not yet recruiting·LLei ZHAO·Phase 2·NCT07352007·110 enrolled
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
Completed·UUniversity of Chicago·Phase 1·NCT03431948·60 enrolled
Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer
Completed·UUniversity Hospital, Ghent·Phase 1·NCT02826564·18 enrolled
Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors
Withdrawn·LLuke, Jason, MD·Phase 1·NCT05469490
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC
Unknown status·WWest China Hospital·Phase 2·NCT04547452·84 enrolled
Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT
Unknown status·SSun Yat-sen University·Phase 2·NCT04169399·30 enrolled
Stereotactic Body Radiotherapy for the Treatment of OPD
Unknown status·IInstitute of Cancer Research, United Kingdom·Phase 2/3·NCT03256981·113 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)